SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul
2018 - 2017 - 2016 - 2015

July 2018 Scleroderma News

Smoking in Systemic Sclerosis (SSc): a Longitudinal European Scleroderma Trials and Research Group Study. The known adverse effect of smoking on bronchial airways and alveoli is observed in SSc patients, but not on the progression of SSc–specific pulmonary or cutaneous manifestations. PubMed, Arthritis Rheumatol, 05/21/2018. (Also see Preventive Care for Pulmonary Involvement)

Blood Levels of CD163 Protein May Be a Biomarker to Detect Systemic Sclerosis, Study Shows. Researchers emphasized that additional studies are needed to determine the exact role of CD163 in the development of systemic sclerosis. Scleroderma News, 06/05/2018. (Also see Prognosis and Mortality)

The effects of upper and lower limb exercise on the microvascular reactivity in limited cutaneous systemic sclerosis (SSc) patients. Our results suggest that arm cranking has the potential to improve the microvascular endothelial function in SSc patients. PubMed, Arthritis Res Ther, 2018 Jun 5;20(1):112. (Also see Raynaud's: Rewarming Tips)

The contemporary management of Systemic Sclerosis (Ssc). Future directions in this field may include combination and maintenance therapy that is currently used in other autoimmune diseases, and tailoring these treatments according to the patients' phenotype. PubMed, Expert Rev Clin Immunol, 06/06/2018. (Also see Scleroderma Treatments – General)

Hearing loss in patients with scleroderma (SSc): associations with clinical manifestations and capillaroscopy. Subjective and objective hearing loss were higher in patients with SSc compared to the control group and also sensorineural hearing loss, abnormal pure tone audiometry, and abnormal speech reception threshold. PubMed, Clin Rheumatol, 06/02/2018. (Also see Autoimmune Ear Diseases)

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Skin gene expression of biomarkers may provide guidance in decision–making about which patients should be considered for aggressive therapies and/or for clinical trials. PubMed, Arthritis Rheumatol, 2018 Jun;70(6):912-919. (Also see Diffuse Scleroderma and Skin Fibrosis)

A Feasibility Study of a Novel Low Level Light Therapy (LTTT) for Digital Ulcers (DUs) in Systemic Sclerosis. LTTT for DUs is safe, feasible and well tolerated. There was an early tentative suggestion of treatment efficacy. PubMed, J Dermatolog Treat, 2018 Jun 4:1-30. (Also see Treatments for Digital Ulcers)

Should all digital ulcers (DUs) be included in future clinical trials of systemic sclerosis (SSc)–related digital vasculopathy? We would encourage the expert SSc community to reconsider the rationale for including only fingertip DUs in future SSc clinical trials, and suggest an agenda for future research. PubMed, Med Hypotheses, 2018 Jul;116:101-104. (Also see Research on Digital Ulcers)

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis (SSc). The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. PubMed, Ann Rheum Dis, 05/31/2018. (Also see Interleukins and Clinical Trials)

Supportive Use of Adipose-Derived Stem Cells in Cell–Assisted Lipotransfer for Localized Scleroderma. Cell–assisted lipotransfer not only improves the survival rate of transplanted fat but also improves skin texture in bleomycin–induced skin fibrosis nude mice. PubMed, Plast Reconstr Surg, 2018 Jun;141(6):1395-1407. (Also see Stem Cell Transplantation)

Go to Scleroderma Medical News: June 2018
 

See ISN News for recent donors. Click Here to Donate.

 

TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.

We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, report bad links, or update page content. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!